The present study concludes that MCC950 shows appropriate in vivo efficacy to repress NLRP3/Caspase-1/IL-1 signaling enough to improve acute stroke outcomes in a MCAO model of stroke (Fig. 6). The gene discussed is NLRP3; the disease is Stroke.